Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VIC-1911 |
Synonyms | |
Therapy Description |
VIC-1911 (TAS-119) is a selective inhibitor of the serine/threonine kinase Aurora A, which may cause disruption of mitotic spindle assembly and chromosome segregation, thus inhibiting cell division and inducing apoptosis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VIC-1911 | TAS-119|TAS-2104 | Aurka Inhibitors 25 | VIC-1911 (TAS-119) is a selective inhibitor of the serine/threonine kinase Aurora A, which may cause disruption of mitotic spindle assembly and chromosome segregation, thus inhibiting cell division and inducing apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05374538 | Phase I | VIC-1911 Sotorasib + VIC-1911 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02134067 | Phase I | VIC-1911 Paclitaxel | Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02448589 | Phase I | VIC-1911 | An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel | Terminated | USA | ITA | ESP | 2 |